abbvie glp-1 Novo pressures compounders as FDA ban takes hold 1 and CB2 receptors to help reduce appetite AbbVie's GLP-1 challenger shows early
Description
I would say thats a research hypothesis that we are currently pursuing

Pivovarova O, Hohn A, Grune T, Pfeiffer AF, Rudovich N

[DOI] [PMC free article] [PubMed] [Google Scholar] 19.Eliasson L., Ma X., Renstrm E., Barg S., Berggren P.-O., Galvanovskis J., Gromada J., Jing X., Lundquist I., Salehi A., et al

This is Novo Nordisk's competitive response to Eli Lilly a stronger injectable to counter the convenience of an oral pill
